Abstract
Safety and immunogenicity of Anti PD-L1 (Atezolizumab) given as an immune primer or concurrently with extended field chemoradiotherapy for node positive locally advanced cervical cancer: an NRG Oncology trial (024)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have